Abstract: Chemopreventive effect of non-steroidal antiinflammatory drugs (NSAIDs) in mammary carcinogenesis was reported in several studies. In this study, the effect of a nonselective cyclooxygenase inhibitor diclofenac (DICLO) in the prevention of N-methyl-N-nitrosourea (NMU)-induced mammary carcinogenesis in Sprague-Dawley female rats was evaluated. NMU was administered to animals intraperitoneally in two doses of 50 mg kg −1 b.w. within postnatal days 42-48. In experiment A (short-term administration), DICLO was administrated intramuscularly (5 mg kg −1 b.w.) every other day, starting 3 days before and for subsequent 25 days after first NMU injection. In experiment B (long-term administration), DICLO was administered in tap water (0.01 mg ml −1 ) continually, starting 7 days before and for subsequent 22 weeks after first NMU dose. The study was terminated 22 weeks after the first dose of NMU in both experiments. After DICLO treatment, tumor frequency per group was reduced in both variants of drug administration: in experiment A by 38% and in experiment B by 39.5%. Moreover, DICLO decreased tumor incidence by 11.5% and delayed tumor latency by 14 days in experiment B. In our preventive-curative experiments DICLO decreased some parameters of NMU-induced rat mammary carcinogenesis, mainly the tumor frequency.
Introduction
Breast cancer presents a serious health issue worldwide. Chemoprevention appears to be an effective way to combat carcinogenesis. Several groups of drugs should be considered for this purpose including NSAIDs showing an impact beyond their anti-inflammatory properties. Recently, their preventive effects in carcinogenesis were reported. Clinical studies reported a pronounced decline in colon (Thun et al. 1991) , mammary gland (Harris et al. 1999) , prostatic (Nelson & Harris 2000) , and lung cancer incidence after long-term NSAID administration (Harris et al 2002) . In vivo, chemopreventive effects of NSAIDs in various types of neoplasia, including breast cancer were reported.
Our group proved the chemopreventive effects of indomethacin administered in drinking water (Môci-ková-Kalická et al. 2001 ), nimesulide applied subcutaneously (Kubatka et al. 2002) , rofecoxib (Kubatka et al. 2003) , etoricoxib (Orendáš et al. 2007) , and celecoxib (Orendáš et al. 2009 ), all administered in the diet to female Sprague-Dawley rats with chemically-induced mammary tumors. Generally, at least 90% of mammary tumors showed malignant features, cribriform carcinoma in situ and invasive adenocarcinomas prevailed; the malignant/benign tumor ratio maintained regardless of oncostatic efficacy (Orendáš et al. 2009 ).
Cyclooxygenase (COX) enzymes (constitutional COX-1 isoform in cells, inducible COX-2 isoform expressed during carcinogenesis and inflammation) belong to fast-response proteins. Expression of COX genes is regulated by many cytokines, growth factors, and oncogenes, preferentially synthetizing prostaglandins (PG). These substances, particularly PGE2 are upregulated in various cancer tissues and the overexpression of COX-2 activity was found in 40% of clinically verified mammary carcinomas (Howe et al. 2001; Hull 2005) . Clear position of COX-2 hyper/expression does not exclude the COX-1 role in carcinogenesis: COX-1 knockout depressed induction of various neoplasias in mice (Chulada et al. 2000) , and COX-2 knockout animals still displayed high levels of PGE 2 in tumors (Howe et al. 2005) . The association of PGE 2 /COX system with HER2/neu, erb-2 overexpression receptor activity represents an im-734 P. Orendáš et al. portant issue. The COX/PG system appears to be associated with aromatase activity -COX-1/COX-2 inhibitors were more effective in estrogen receptor positive mammary tumors, which may be important for clinical practice. However, this trend does not apply to some NSAIDs, aspirin in particular (Howe & Lippman 2008) .
DICLO belongs to NSAIDs with preferential COX-1 activity inhibition, but it possesses anti-COX-2 properties too. This compound belongs to the most commonly used drugs in medical practice, but we did not find any report on its use in experimental mammary carcinogenesis.
Material and methods
Female Sprague-Dawley rats obtained from Charles River Laboratories (Sulzfeld, Germany) aged 30-35 days, weighing 101-125 g were used in the experiment. The animals were adapted to standard vivarium conditions with the temperature 23 ± 2
• C, relative humidity 60-70%, artificial regimen light : dark = 12:12 h, with light on from 7.00 h (light intensity 150 lux per cage, light source: fluorescent lamps Tesla -40W). During the experiment the animals were fed the MP diet (Top Dovo, Dobrá Voda) and drank tap water ad libitum. Diclofenac /Diclofenac sodium/ (DICLO), (produced by: Ningbo Smart Chemical & Pharmaceutical Co., LTD, Ningbo, Zhejiang, China, provided by: Zentiva a.s., Hlohovec, Slovakia) was administered intramuscularly in the dose of 5 mg kg −1 b.w. (experiment A) or in tap water in the concentration of 0.01 mg ml −1 (experiment B), respectively. Mammary carcinogenesis was induced by N-methyl-N-nitrosourea (NMU) (Sigma, Deisenhofen, Germany), administered intraperitoneally in two doses, each per 50mg/kg b.w., in a six-day interval between 42 nd -48 th postnatal days to all animals. NMU was freshly prepared by dissolving in isotonic saline solution (0.5 ml per animal). Chemoprevention with DICLO began 3 days before the first carcinogen administration, lasted during the carcinogen administration and 25 days after the first dose of NMU, being injected every other day (experiment A, short-term administration) or 7 days before carcinogen administration and lasted until the end of the experiment (experiment B, long-term administration). Both experiments lasted 22 weeks after the first carcinogen dose (see Fig. 1 ). Two groups of animals were used in experiments A and B: control (CONT) without DICLO /8 or 20 animals, respectively/ and the other with DICLO administration /11 and 24 animals, respectively/.
The animals were weekly weighed and palpated in order to record the incidence, number, location, and size of tumors. In the 22 nd week of the experiment, the animals were sacrificed by quick decapitation. Mammary tumors were excised, weighed, and tumor size was recorded. Tissue sample of each mammary tumor was routinely formalin-fixed and paraffin-embedded. The tumors were classified according to the criteria for the classification of rat mammary tumors (Russo & Russo, 2000) . The following basic parameters of mammary carcinogenesis were assessed in each group: 1. tumour incidence as the percentage of tumor-bearing animals, 2. tumor frequency per group as the average number of tumors per group, 3. tumor frequency per animal as the average number of tumors per tumor-bearing animals, 4. average tumor volume, 5. latency period determined by the period between the first carcinogen dose to the appearance of the first tumor. The effect of a chemopreventive agent on body weight gain (evaluated from the initiation until the end of the experiment), food and water intake were evaluated. Food and water intake during 24 h was recorded in the 6 th , 11 th , 16 th , and 21 st week after carcinogen administration in 8 measurements (twice in a given week). Tumor incidence was evaluated by Mann-Whitney U-test, other parameters by one-way analysis of variance or Kruskal-Wallis test (P < 0.05), respectively. Tumor volumes were calculated according to the formula: V (mm 3 ) = π × S 2 1 × S2/12; (S1 < S2), S1 and S2 were measured perpendicularly.
Results
The effect of DICLO in female Sprague-Dawley rats' mammary carcinogenesis is presented in Tables 1 and   2 . DICLO significantly decreased the tumor frequency in experiment A (Table1). Average daily dose of DICLO was 0.94 mg kg −1 b.w. (experiment B). DICLO in the experiment B altered the final parameters of mammary carcinogenesis; tumor frequency per group decreased by 39.5%, tumor frequency per animal by 31.5%. The latency period was prolonged by 14 days (by 16%). Dynamic observation showed maximal effectiveness of DI-CLO on tumor incidence and frequency per group during week 16-20 of the experiment B (Figs 2, 3) . The body weight gain in DICLO animals decreased only by 5% at final analysis and the food and water intake was practically unchanged (data not shown).
Cribriform, papillary, mixed papillary/cribriform and cribriform/comedo carcinomas were most frequent lesions in all experimental groups. In both experiments, the body weight gain at final analysis and the food and water intake were practically unchanged in DICLO animals (data not shown). No macroscopic changes were observed in the analysed organs.
Discussion
In addition to beneficial effects in rheumatic disease, NSAIDs display preventive effects in carcinogenesis too. Their chemopreventive effect was proved by several experimental (in female rats) and clinical studies. The experiments with indomethacin applied in drinking water (20 µg ml −1 water) performed by our group in DMBAinduced mammary carcinogenesis in female SpragueDawley rats decreased mammary tumor incidence by 63%, tumor frequency per group by 88%, and prolonged latency by 63% in comparison with controls (Môciková-Kalická et al. 2001) . Tumor-suppressive effect of nimesulide (applied subcutaneously twice a week) was found by our group in NMU-induced mammary carcinogenesis in female Sprague-Dawley rats. No oncostatic effect of nimesulide was found in the above mentioned experiment in DMBA-induced mammary carcinogenesis (Kubatka et al. 2002) . In another study of our group, preventive effect of dietary administered rofecoxib in NMU-induced mammary carcinogenesis in female Sprague-Dawley rats was confirmed by decreased tumor incidence and frequency at both doses we used (0.01 mg g −1 , 0.05 mg g −1 diet). Latency period was prolonged by 0.5% and 10%, respectively (Kubatka et al. 2003) . Our next study focused on prevention of NMU-induced mammary carcinogenesis by etoricoxib administered in a diet to female Sprague-Dawley rats.
We found a tumor suppressive effect at a higher dose (0.025 mg g −1 diet) documented by a decrease in tumor incidence, tumor frequency per group and prolonged latency by 7.3% (Orendáš et al. 2007) . Abou-Issa et al. (2001) reported inhibition in DMBA-induced mammary carcinogenesis in female Sprague-Dawley rats by celecoxib (0.25 g kg −1 , 0.50 g kg −1 , 1.00 g kg −1 or 1.50 g kg −1 diet) administered with diet. Similar results yielded our group -decrease in tumor incidence and frequency per animal and group was found during 20-week administration of celecoxib (1.67 g kg −1 chow) in NMUinduced mammary carcinogenesis; co-administration of melatonin reinforced the effect of celecoxib (Orendáš et al. 2009 ).
DICLO in both experiments of present study decreased particularly the frequency of mammary tumors almost by 40%, latency was delayed by 14 days in experiment B. Apparent differences in DICLO antineoplastic efficacy between short (exp. A) and longer drug administration (exp. B) were not found. The incidence dynamics during the longer -B variant (preventivecurative form) of our observation has to be emphasized: a marked inter-group difference in incidence occurred between weeks 16-20 of the experiment. If we had ceased the experiment at that time, we probably would have register a marked effect of DICLO comparable with that of Abou-Issa et al. (2001) in DMBA-induced mammary carcinogenesis, with 17 weeks of celecoxib administration. Therefore we postulate the need for the standardization of chemopreventive experiments' duration, with 20-24 weeks of duration after carcinogenesis induction at minimum.
Recent clinical studies summarised broad retrospective data on subjects with long-term (over 5 years) NSAID medication, however an increase in thromboembolism in patients treated with COX-2 inhibitors disabled extensive use of these drugs; celecoxib is probably an exception (Harris et al. 2006) . Recent reviews docu-mented 36% effectiveness on tumor incidence decrease in NSAID-treated patients in average, about 39% effectiveness in breast cancer (Harris 2007) . Agrawal & Fentiman (2008) and Takkouche et al. (2008) reported on about 20% decrease in neoplasias, including breast cancer, using various types of NSAIDs. COX-2 polymorphism and interaction with other drugs could modify the final effect.
Cancer chemoprevention as a "byproduct" of chronic treatment of arthritic patients using NSAIDs, of atherosclerotic complications in hyperlipoproteinemic subjects (using statins) and patients with type 2 diabetes (using peroral antidiabetics, especially glitazones) bring an interesting and fruitful contribution to the possibilities of decreasing cancer incidence. The role of experimental oncology is to elucidate the origin and the mechanisms of new ways in cancer chemoprevention.
